BPC-157 vs TB-500
BPC-157 and TB-500 are unrelated synthetic peptides often discussed together in tissue-repair research. This page compares their origin, structure, proposed mechanisms, evidence base, regulatory status and the analytical issues raised by combined blends.
BPC-157 is a 15-residue synthetic peptide whose sequence was taken from a larger protein described in gastric juice. TB-500 is a name applied to synthetic peptides derived from thymosin β4, most often a short fragment around its actin-binding region. The two share no sequence similarity and were developed through entirely separate lines of research.
They are grouped together because both have been studied in animal models of tendon, muscle, skin and other soft-tissue injury, and because research catalogs frequently list them side by side or in a single vial. Human evidence for either compound as supplied in research catalogs is limited, and both were reviewed by the FDA's compounding advisory committee in July 2026.
Side-by-side
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Origin | Partial sequence of a protein reported in human gastric juice; fully synthetic | Derived from thymosin β4, a 43-residue actin-binding protein; synthetic |
| Length | 15 amino acids (pentadecapeptide) | Variable by supplier; commonly a short N-acetylated fragment, sometimes full-length thymosin β4 |
| Structure | Linear, unmodified; sometimes supplied as an acetate or arginine salt | Linear; fragment forms are typically N-terminally acetylated; identity varies between sources |
| Proposed targets | Angiogenic and nitric oxide signaling, growth factor receptor expression (proposed, not established) | G-actin sequestration and cell migration, inherited from thymosin β4 biology |
| Research areas | Rodent models of gastrointestinal, tendon, ligament and muscle injury | Animal and in-vitro models of wound healing, cardiac and corneal injury (mostly on thymosin β4) |
| Evidence level | Preclinical; no robust controlled human trials | Preclinical for TB-500 itself; clinical studies exist only for thymosin β4 |
| FDA / compounding | Not FDA-approved; PCAC voted 8-6-1 in July 2026 to recommend 503A bulk listing, no final FDA action | Not FDA-approved; PCAC voted 8-6-1 in July 2026 to recommend 503A bulk listing, no final FDA action |
| WADA | Prohibited under S0 (non-approved substances) | Prohibited under S2 (thymosin β4 and its fragments) |
| Analytical pitfalls | Salt form and counter-ion content; deletion or truncation impurities | Confirming which sequence is actually present (fragment vs full-length); acetylation state |
| Storage | Lyophilized at -20 °C, protected from light and moisture | Lyophilized at -20 °C, protected from light and moisture; avoid repeated freeze-thaw |
Different origins and structures
BPC-157 is a single defined sequence of 15 residues and is usually characterized against that one expected mass. TB-500 is less well defined: the name has been used for a short acetylated fragment of thymosin β4, for other fragments, and occasionally for the full 43-residue protein. The FDA noted variable sequences and salt forms as unresolved identity questions when the compounding committee reviewed both compounds in 2026. For any lot labeled TB-500, the certificate of analysis should state the exact sequence the mass was checked against.
Mechanism and evidence quality
Proposed mechanisms for BPC-157 involve angiogenesis, nitric oxide pathways and growth factor signaling, drawn mostly from rodent studies carried out by a small number of research groups; none is firmly established. TB-500's proposed activity is inferred from thymosin β4, which binds monomeric actin and has been linked to cell migration and wound repair in animal and cell models. The FDA noted that no direct human studies of TB-500 itself exist. Clinical studies of thymosin β4 should not be read as evidence for short fragments.
Why combined blends appear in catalogs
Because the two compounds are discussed in overlapping areas of tissue-repair research, some research catalogs offer premixed vials that contain both peptides. These blends are a convenience format rather than a defined compound. No approved product combines them, and the published animal literature has mostly studied each compound separately. A blend makes the quantity of each component, and its stability alongside the other, a separate question that a single-compound certificate does not answer.
Verifying two peptides in one vial
A blend needs separate identity confirmation for each peptide. Mass spectrometry should show the expected mass for BPC-157 and for the specific TB-500 sequence, and HPLC should resolve two main peaks rather than one. A single overall purity figure says little on its own: the certificate should report the peak area and assigned identity of each component, the ratio between them, and the impurities linked to each. Net peptide content is harder to state for a mixture, and co-eluting impurities can be mistaken for either component. See HPLC and mass spectrometry explained.
Frequently asked questions
Are BPC-157 and TB-500 the same thing?
No. BPC-157 is a 15-residue peptide taken from a gastric juice protein sequence, while TB-500 refers to synthetic peptides derived from thymosin β4. They have unrelated sequences, different proposed mechanisms and separate research literatures. They are often mentioned together because both have been studied in animal models of soft-tissue injury.
Is BPC-157 or TB-500 FDA approved?
Neither is approved by the FDA for any use. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8-6-1 for each to be added to the 503A bulk drug substances list. That vote is advisory only; the FDA must act through notice-and-comment rulemaking, and no final action has been announced.
How is a BPC-157/TB-500 blend tested?
Each peptide needs its own identity confirmation. Mass spectrometry should detect the expected mass for both components, and HPLC should show two resolved main peaks with each one assigned and quantified. A useful certificate reports the ratio of the two peptides and the impurities linked to each, rather than a single combined purity figure.
Full entries
- BPC-157
BPC-157 is a synthetic 15-amino-acid peptide whose sequence was derived from a protein fraction of gastric juice. It is studied mainly in rodent models of gastrointestinal, tendon and soft-tissue injury and is not approved for any use.
- TB-500
TB-500 is a research name most often applied to a short synthetic N-acetylated fragment of thymosin β4, Ac-LKKTETQ, but it is also used loosely for full-length thymosin β4. There are no direct human studies of the fragment.
Cite this page